The purpose of the study is to determine if a newly developed rapid test can detect levels of bictegravir (BIC), dolutegravir (DTG) or cabotegravir (CAB) in a person’s blood.
You may be eligible to participate if you have been stable on your medication for at least 2 months.
Participants may receive up to $75 in compensation per completed visit.
For more information you can contact 617.927.6450 or [email protected].